ArticleeLife2019
Transcriptional down-regulation of
Open access · goldAbstract read
In one paragraph
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Mechanisms of transcriptional regulation of CCR5, which is the co-receptor for R5-tropic HIV and is also involved in other disease processes.Biochemical Society transactions · 2026Review
- Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection.Current opinion in HIV and AIDS · 2025Review
- Transposable elements may enhance antiviral resistance in HIV-1 elite controllers.Genome biology · 2025Article
- Review
- JAK/STAT signaling pathway affects CCR5 expression in human CD4Science advances · 2024Article
- Transposable elements may enhance antiviral resistance in HIV-1 elite controllers.bioRxiv : the preprint server for biology · 2023Article
- Reduced CCR5 expression among Uganda HIV controllers.Retrovirology · 2023Article
- MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4iScience · 2022Article
- Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry.Nature communications · 2022Article
- Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.Journal of virology · 2022Article
- CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.Frontiers in immunology · 2022Review
- Omic Technologies in HIV: Searching Transcriptional Signatures Involved in Long-Term Non-Progressor and HIV Controller Phenotypes.Frontiers in immunology · 2022Review
- Naive infection predicts reservoir diversity and is a formidable hurdle to HIV eradication.JCI insight · 2021Article
- The CD8Microbiology and molecular biology reviews : MMBR · 2021Review
- Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status.iScience · 2021Article
- Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers.Frontiers in immunology · 2021Article
- Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders.Cellular and molecular life sciences : CMLS · 2019Review
- Article
- Transcriptional down-regulation ofeLife · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Elena Gonzalo-GilSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.ORCID 0000-0002-0409-3094
Patrick B RapuanoSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.
Uchenna IkediobiSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.
Rebecca LeibowitzSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.
Sameet MehtaYale Center for Genome Analysis Bioinformatics group, Yale University School of Medicine, New Haven, United States.
Ayse K CoskunSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.
J Zachary PorterfieldSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.
Teagan D LampkinInfectious Diseases Section, Dallas VA Medical Center, Dallas, United States.
Vincent C MarconiAtlanta VA Medical Center, Emory University School of Medicine, Atlanta, United States.
David RimlandAtlanta VA Medical Center, Emory University School of Medicine, Atlanta, United States.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard University, Cambridge, United States.
Steven DeeksDepartment of Medicine, University of California San Francisco, San Francisco, United States.ORCID 0000-0001-6371-747X
Richard E SuttonSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, United States.ORCID 0000-0001-7418-2378
Yale University · USEmory University · USDallas VA Medical Center · USRagon Institute of MGH, MIT and Harvard · USUniversity of California, San Francisco · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUnsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4MThe impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6MVirology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2011 to 2015
$29.5MAlcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7MAlcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7MTRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1MHost Genetic Control of HIVDP1DA036463 · NIDA · YALE UNIVERSITY · PI SUTTON, RICHARD · 2013 to 2017
$3.7MHigh Performance Computing Instrumentation for the Yale Center for Genome AnalysiS10OD018521 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2015 to 2015
$890kNCATS NIH HHS UL1 TR001863NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U10 AA013566NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI060354NIAID NIH HHS R24 AI067039NIAID NIH HHS T32 AI007517NIAID NIH HHS U19 AI096109NIDA NIH HHS DP1 DA036463NIDA NIH HHS DP1DA036463NIH HHS P30AI050409NIH HHS S10 OD018521
Abstract
HIV +Elite and Viremic controllers (EC/VCs) are able to control virus infection, perhaps because of host genetic determinants. We identified 16% (21 of 131) EC/VCs with CD4 +T cells with resistance specific to R5-tropic HIV, reversed after introduction of
Indexed as
Disease ResistanceDown-RegulationFamilyHIV Long-Term SurvivorsAdultAgedCD4-Positive T-LymphocytesCells, CulturedFemaleHIV-1HIV InfectionsHumansMacrophagesMaleMiddle AgedReceptors, CCR2CCR2 protein, humanCCR5 protein, humanReceptors, CCR2Receptors, CCR5ccr2ccr5elite controllersHIVhumaninfectious diseasemicrobiologytranscriptionviremic controllersvirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.